Scientists say: data on the effectiveness of the Pfizer vaccine is sorely lacking

As soon as Pfizer representatives triumphantly announced the effectiveness of their COVID-19 vaccine on Monday, their comments were immediately criticized. The remarks do not lie in the political or economic plane, but relate exclusively to the intricacies of the treatment of infectious diseases. The main critic is William Hazeltin, president of Access Health International, a Harvard professor and founder of several medical companies.

Hazeltin first pointed out that Pfizer only reported effective immunizations for 94 patients, but did not provide any statistical information. Who are these people, what country do they live in, what kind of life do they lead? Old people or young people, do they have chronic diseases or not? Doctors cannot evaluate a drug without knowing these critical data.

The second important note: what results were obtained in the control group, which was given a placebo? What are the data on the difference in symptoms in patients with the vaccine and placebo, what were the drug intake schedules, where are the descriptions of personal side effects? In its current form, Pfizer's statement looks like an encouraging cry, for now nothing more. But all this does not compare with the main question - what is the situation with asymptomatic carriers of coronavirus who received the vaccine?

This is a fundamental point, because the concept of immunization does not at all mean getting rid of the virus completely. This means that a vaccinated person may be an asymptomatic carrier and continue to infect others. Thus, the effectiveness of the Pfizer vaccine in the third phase of trials is encouraging, but the data are still too few.